首页 / 产品中心 / 单克隆抗体 /

货号: YP-rAb-17292
促销价:

产品介绍

反应种属
Human,Mouse,Rat
应用范围
WB,IHC,IF,IP,ELISA
抗体类型
单克隆抗体
基因名称(Gene Name)
MYH9
蛋白名称
Myosin-9 (Cellular myosin heavy chain, type A) (Myosin heavy chain 9) (Myosin heavy chain, non-muscle IIa) (Non-muscle myosin heavy chain A) (NMMHC-A) (Non-muscle myosin heavy chain IIa) (NMMHC II-a) (NMMHC-IIA)
分子量(DA)
227kD
免疫原
特异性
Endogenous
组成
PBS, 50% glycerol, 0.05% Proclin 300, 0.05%BSA
来源
Monoclonal, Rabbit,IgG
稀释比例
IHC 1:200-1:1000; WB 1:2000-1:10000; IF 1:200-1:1000; ELISA 1:5000-1:20000; IP 1:50-1:200; Note: For IHC, we suggest antigen retrieval with TE buffer pH 9.0
纯化工艺
Protein A
浓度
0.5 mg/ml
储存
-15°C to -25°C/1 year(Do not lower than -25°C)
其他名称
MYH9;Myosin-9 (Cellular myosin heavy chain, type A) (Myosin heavy chain 9) (Myosin heavy chain, non-muscle IIa) (Non-muscle myosin heavy chain A) (NMMHC-A) (Non-muscle myosin heavy chain IIa) (NMMHC II-a) (NMMHC-IIA)
背景
This gene encodes a conventional non-muscle myosin; this protein should not be confused with the unconventional myosin-9a or 9b (MYO9A or MYO9B). The encoded protein is a myosin IIA heavy chain that contains an IQ domain and a myosin head-like domain which is involved in several important functions, including cytokinesis, cell motility and maintenance of cell shape. Defects in this gene have been associated with non-syndromic sensorineural deafness autosomal dominant type 17, Epstein syndrome, Alport syndrome with macrothrombocytopenia, Sebastian syndrome, Fechtner syndrome and macrothrombocytopenia with progressive sensorineural deafness. [provided by RefSeq, Dec 2011],
功能
Disease:Defects in MYH9 are the cause of Alport syndrome with macrothrombocytopenia (APSM) [MIM:153650]. APSM is an autosomal dominant disorder characterized by the association of ocular lesions, sensorineural hearing loss and nephritis (Alport syndrome) with platelet defects.,Disease:Defects in MYH9 are the cause of Epstein syndrome (EPS) [MIM:153650]. EPS is an autosomal dominant disorder characterized by the association of macrothrombocytopathy, sensorineural hearing loss and nephritis.,Disease:Defects in MYH9 are the cause of Fechtner syndrome (FTNS) [MIM:153640]. FTNS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are small and poorly organized. Additionally, FTNS is distinguished by Alport-like clinical features of sensorineural deafness, cataracts and nephritis.,Disease:Defects in MYH9 are the cause of macrothrombocytopenia with progressive sensorineural deafness (MPSD) [MIM:600208]. MPSD is an autosomal dominant disorder characterized by the association of macrothrombocytopathy and progressive sensorineural hearing loss without renal dysfunction.,Disease:Defects in MYH9 are the cause of May-Hegglin anomaly (MHA) [MIM:155100]. MHA is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukokyte inclusions appearing as highly parallel paracrystalline bodies.,Disease:Defects in MYH9 are the cause of non-syndromic sensorineural deafness autosomal dominant type 17 (DFNA17) [MIM:603622]. DFNA17 is a form of sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA17 is characterized by progressive hearing impairment and cochleosaccular degeneration.,Disease:Defects in MYH9 are the cause of Sebastian syndrome (SBS) [MIM:605249]. SBS is an autosomal dominant macrothrombocytopenia characterized by thrombocytopenia, giant platelets and leukocyte inclusions that are smaller and less organized than in May-Hegglin anomaly.,Disease:Subjects with mutations in the motor domain of MYH9 present with severe thrombocytopenia and develop nephritis and deafness before the age of 40 years, while those with mutations in the tail domain have a much lower risk of noncongenital complications and significantly higher platelet counts. The clinical course of patients with mutations in the four most frequently affected residues of MYH9 (responsible for 70% of MYH9-related cases) were evaluated. Mutations at residue 1933 do not induce kidney damage or cataracts and cause deafness only in the elderly, those in position 702 result in severe thrombocytopenia and produce nephritis and deafness at a juvenile age, while alterations at residue 1424 or 1841 result in intermediate clinical pictures.,Domain:The rodlike tail sequence is highly repetitive, showing cycles of a 28-residue repeat pattern composed of 4 heptapeptides, characteristic for alpha-helical coiled coils.,Function:Cellular myosin that appears to play a role in cytokinesis, cell shape, and specialized functions such as secretion and capping.,similarity:Contains 1 IQ domain.,similarity:Contains 1 myosin head-like domain.,subunit:Interacts with PDLIM2 (By similarity). Myosin is a hexameric protein that consists of 2 heavy chain subunits (MHC), 2 alkali light chain subunits (MLC) and 2 regulatory light chain subunits (MLC-2).,tissue specificity:In the kidney, expressed in the glomeruli. Also expressed in leukocytes.,

展开

产品详情

客户数据及评论 (0)

折叠内容

文献引用

折叠内容

优品生物的抗体,可以回收利用几次?

首先,一般抗体不推荐客户回收利用,抗体使用之后缓冲体系已经发生改变,不同客户在回收抗体的保存条件上也会有差异,所以抗体回收使用效果无法保证。另外,优品生物也做过一批抗体回收验证测试,测试结果显示不同抗体可回收次数不同,一般效价越高的抗体,可重复使用的次数越多,客户可根据实验情况来确定。
注:我们将孵育完毕后剩余的抗体回收到离心管中置于4℃保存,效价高的抗体可至少保存1周,至少重复利用3次。

收起

优品生物作为国产抗体品牌的优势?

优品生物是国产品牌,通过聚焦抗体与酶核心技术,致力于打破国际技术的垄断,我们拥有包括兔多克隆抗体、小鼠单克隆抗体、兔单克隆抗体的生产研发平台,同时也有包括WB,IP在内的检测平台,我们对每一支自产的抗体进行了严格的检测。当然,我们部分直销地区也可以帮客户代购进口品牌的产品。同时也有抗体定制服务。优品生物l抗体优势:1,严自检,保质量;2产品多,指标全;3,价格低,货期短。

收起

优品生物抗体成分?

优品生物抗体成分在平时工作当中,常会有客户咨询我们的抗体用的什么buffer进行保存,一般来说,我们的buffer的成分是:PBS含0.03%的proclin300、0.05%牛血清白蛋白、50%甘油;也有一些是PBS含0.03%的proclin300,50%甘油。防腐剂 Proclin 300活性成分主要是2-甲基-4-异噻唑啉-3-酮(MCI)和5-氯-2-甲基-4-异噻唑啉-3-酮(CMCI)。ProClin生物灭活剂能够迅速穿透细胞膜,抑制对细胞呼吸至关重要的特定酶,因此一接触微生物有机体就会立即抑制细胞活性。ProClin的多个特定毒性位点可以防止微生物产生高水平的耐药性。

收起

实验方案

折叠内容
>